New drug combo shows promise for tough cancers
NCT ID NCT04798781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of two drugs—telatinib (a pill that blocks tumor blood vessels) and Keytruda (an immunotherapy that helps the immune system attack cancer)—in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see if the combo could slow cancer growth. The study is now complete, and results will show whether this approach is safe and effective enough to pursue in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telatinib (a targeted cancer pill) and Keytruda (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced stomach or liver cancer who have run out of standard therapies.
What could go wrong
This is a very small, early-phase trial with only 16 participants, so results may not apply to larger groups. The combination may cause significant side effects or fail to improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CS Cancer Beverly Hills
Beverly Hills, California, 90211, United States
-
CS Cancer at The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
CS Cancer at the Samuel Oschin Cancer Center
Los Angeles, California, 90048, United States